SynthesisThoracic cancer2018
Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis.
Synthesis in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Is There a Place for Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer?Current oncology (Toronto, Ont.) · 2022Pooled it
- Postoperative Adjuvant Therapy Benefits Non-pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real-World Study.Thoracic cancer · 2025Article
- Prognostic value of the cholesterol-dependent nutritional prognostic index in patients receiving adjuvant chemotherapy after radical esophageal cancer treatment.European journal of medical research · 2024Article
- Optimal extent of lymphadenectomy improves prognosis and guides adjuvant chemotherapy in esophageal cancer: A propensity score-matched analysis.World journal of gastrointestinal surgery · 2024Article
- PET/CT deep learning prognosis for treatment decision support in esophageal squamous cell carcinoma.Insights into imaging · 2024Article
- Postoperative adjuvant immunotherapy for pathological stage II-IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates.Frontiers in medicine · 2024Article
- Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review.JCO oncology practice · 2023Article
- Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node-positive esophageal squamous cell carcinoma: Is oral chemotherapy promising?Cancer medicine · 2023Article
- Adjuvant chemotherapy in node-positive patients after esophagectomy for esophageal squamous cell carcinoma.Thoracic cancer · 2023Article
- Impact of adjuvant chemotherapy for radically resected esophageal squamous cell carcinoma: a propensity score matching analysis.Frontiers in surgery · 2023Article
- Clinical Trends in Management of Locally Advanced ESCC: Real-World Evidence from a Large Single-Center Cohort Study.Cancers · 2022Article
- Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma.World journal of gastrointestinal oncology · 2022Article
- A novel prognostic model: which group of esophageal squamous cell carcinoma patients could benefit from adjuvant chemotherapy.Annals of translational medicine · 2022Article
- Correlates of Long-Term Survival of Patients with pN+ Esophageal Squamous Cell Carcinoma after Esophagectomy.Journal of oncology · 2021Article
- Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.BioMed research international · 2021Article
- Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma.Annals of gastroenterological surgery · 2020Review
- Adjuvant Therapy for Esophageal Squamous Cell Carcinoma.The Korean journal of thoracic and cardiovascular surgery · 2020Article
- The Role of β-Arrestin1 in Esophageal Squamous Cell Carcinoma.OncoTargets and therapy · 2020Article
- Clinical Value of Tumor Marker Index Based on Preoperative CYFRA 21-1 and SCC-Ag in the Evaluation of Prognosis and Treatment Effectiveness in Patients with Esophageal Squamous Cell Carcinoma.OncoTargets and therapy · 2020Article
- The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa-IVa lower thoracic oesophageal squamous cell carcinoma.World journal of surgical oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer and most clinically curable patients are diagnosed with locally advanced disease. While the efficacy of preoperative treatment is relatively clear and well characterized, the effect of postoperative treatment, especially postoperative chemotherapy, remains controversial, and its role in the treatment strategy is obscure. We conducted an updated meta-analysis to include recent developments.
methodsA comprehensive search in the PubMed, Embase, and Cochrane databases was performed to identify studies published from the inception of each database to February 2018. The overall survival (OS) and disease-free survival (DFS) rates of patients treated with and without postoperative chemotherapy were analyzed and compared. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the associations between postoperative chemotherapy and patient survival. Potential publication bias was assessed using Egger's line regression test.
resultsA total of nine studies, including three randomized controlled trials and six retrospective studies, were retrieved from the databases, comprising a total of 1684 cases. The results showed that postoperative chemotherapy could improve OS (HR 0.78, 95% CI 0.66-0.91; P = 0.002) and DFS (HR 0.72, 95% CI 0.6-0.86; P < 0.001).
conclusionsThe current meta-analysis supports postoperative chemotherapy as an independent favorable prognostic factor for ESCC, which could improve both OS and DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.